Enliven Therapeutics, Inc.
Company Stats
- Market Cap
- $3.4B
- as of Sep 30, 2026
- Shares Outstanding
- 73.3M
- Free Float
- 62.2%
Income Statement
- Operating Income
- -$119.7M
- Net Income
- -$103.7M
- EBITDA
- -$119.4M
Cash Flow
- Free Cash Flow
- -$70.5M
- FCF Yield
- -2.1%
- Owner FCF Yield
- -3.1%
Balance Sheet
- Cash & Equivalents
- $98.9M
Returns & Capital
- SBC, 3Y Avg
- $22.4M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | — | -$70.5M | — |
| FY2024 | — | -$73.2M | — |
| FY2023 | — | -$61.4M | — |
| FY2022 | — | -$32.7M | — |
| FY2021 | — | -$46.8M | — |
Annual filing data through FY ended December 31, 2025; shares and float as of November 3, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Drug Pricing and PBM Scrutiny: Medicare Rulemaking Gains Detail
Stronger demand supports expansion as pricing diverges